Anumana, a leading AI-driven health technology company, announced that the Centers for Medicare & Medicaid Services (CMS) has recognized its low ejection fraction (LEF) ECG-AI™ technology in the 2025 Hospital Outpatient Prospective Payment System (OPPS) final rule under APC 5734. This approval enables outpatient facilities to receive reimbursement for using Anumana’s ECG-AI service to detect LEF in adults at risk for heart failure, supporting early identification of cardiac dysfunction.
“The new CMS reimbursement ruling reflects our commitment to expanding access to our ECG-AI technology and underscores our leadership in AI-enabled cardiovascular care,” said Maulik Nanavaty, CEO of Anumana. “This important milestone will help eliminate financial barriers to adopting ECG-AI, making it easier to integrate into routine care and ultimately improving outcomes in cardiovascular disease management.”
Anumana’s ECG-AI™ technology, which was granted Category III CPT codes (0764T and 0765T) in 2023, utilizes advanced AI to turn standard ECG data into a powerful diagnostic tool for cardiovascular health. By detecting subtle patterns in ECGs that may signal underlying conditions, ECG-AI™ aids healthcare providers in making earlier, more accurate diagnoses, which can lead to better patient outcomes.
About Anumana
Anumana is a leading AI-driven health technology company focused on revolutionizing cardiovascular care by decoding the electrical language of the heart. Founded by nference in collaboration with Mayo Clinic, Anumana combines the clinical and technical expertise of both organizations to develop ECG-AI™ technology, transforming standard ECG readings into clinically meaningful, real-time insights for clinicians.
Anumana’s software-as-a-medical device (SaMD) solutions are designed to detect diseases earlier using routine ECGs, empowering clinicians to improve care with AI-driven insights.
The company has received FDA Breakthrough Device Designation for four of its ECG-AI-powered algorithms, including those for low ejection fraction, pulmonary hypertension, cardiac amyloidosis, and hyperkalemia. Anumana’s flagship ECG-AI™ LEF algorithm is currently available in the U.S. and under review in Europe.
